Få nyheter om vad som händer på UIC och med UIC-bolagen direkt i din inkorg.
Pelago Bioscience AB and Karo Bio AB have today entered into a commercial license agreement and scientific collaboration regarding the use of the Cellular Thermal Shift Assay (CETSATM) for determination and quantification of drug-target interactions. Under the agreement, Pelago Bioscience grants Karo Bio a license to the CETSA method for use and applications within Karo Bio’s research & development. Pelago Bioscience will, through the agreement, and by access to Karo Bio’s expertise and knowledge, particularly with respect to the nuclear hormone receptor family, validate application of the CETSA method as relevant for the development of novel pharmaceuticals on this important drug target class. Other Terms and Conditions associated with the Agreement are undisclosed.
”We are excited about this opportunity to validate CETSA within this important target class and are proud to work with Karo Bio, who are such well renowned experts in the field’, says Michael Dabrowski CEO of Pelago Bioscience. ‘Karo Bio’s acquisition of a license to the CETSA method is a quality stamp and measure of the applicability and potential importance of CETSA in targeted drug discovery.”
Maria Sjöberg, VP and Head of Preclinical R&D at Karo Bio commented: ”The CETSA method enables us to determine target engagement in relation to specific target classes and we believe that this will aid our development of novel therapies in the areas of autoimmune disease, inflammation and cancer. This combined license and collaborative agreement will enable us to employ the CETSA technology faster and more efficiently.”
Pelago Bioscience has received business development support through Uppsala Innovation Centre’s program UIC Business Lab and is today included in the program UIC Business Prep.
Michael Dabrowski, CEO
Pelago Bioscience AB
tel. +46 (0)730 715 334
About Pelago Bioscience AB
Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSATM) for use in determination and quantification of drug-target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies will be able to make better and more informed decisions at earlier stages in their projects. This will reduce time and money spent on the wrong compounds and allow faster development of more efficacious new drugs.